Jawless fish may hold key to effective brain cancer treatment: Report

Representative image

A chemical found in jawless parasitic fish can be used to deliver anti-cancer drugs directly to brain tumours, as well as lead to more effective treatments for trauma and stroke, a study has found.

The research, published in the journal Science Advances, found that molecules from the immune system of the parasitic sea lamprey may also be combined with a wide array of other therapies, offering hope to treat disorders like multiple sclerosis, Alzheimer's disease or even traumatic injuries.

"We believe it could be applied as a platform technology across multiple conditions," said Eric Shusta, a professor at the University of Wisconsin-Madison in the US.

When injected into the bloodstream, many drugs cannot reach targets in the brain as the blood-brain barrier prevents large molecules from leaving the blood vessels in the brain, researchers said.

In conditions such as brain cancer, stroke, trauma and multiple sclerosis, however, the barrier becomes leaky in and around the disease locations, researchers said.

The study found that leaky barrier offers a unique point of entry, allowing molecules to access the brain and deliver drugs precisely on target.

"Molecules like this normally couldn't ferry cargo into the brain, but anywhere there's a blood-brain barrier disruption, they can deliver drugs right to the site of pathology," Shusta said in a statement.

Researchers said that the technology takes advantage of the fact that many diseases disrupt body's natural defense mechanism -- the blood-brain barrier, which lines the blood vessels of the central nervous system, protecting the brain from circulating toxins or pathogens.

They also linked the molecules to a chemotherapy called doxorubicin. The treatment prolonged survival in mouse models of glioblastoma, an incurable cancer.

"This could be a way to hold therapies in place that don't otherwise accumulate well in the brain so they can be more effective," said Ben Umlauf from the University of Wisconsin-Madison.

"There are several disease processes that disrupt the blood-brain barrier and we could conceive of delivering a variety of different therapies with these molecules," said John Kuo from the University of Texas in the US.


(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)

Dear Reader,


Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.

We, however, have a request.

As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.

Support quality journalism and subscribe to Business Standard.

Digital Editor

Business Standard is now on Telegram.
For insightful reports and views on business, markets, politics and other issues, subscribe to our official Telegram channel